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Introduction: Many severe COVID-19 patients require respiratory support and
monitoring. An intermediate respiratory care unit (IMCU) may be a valuable element for
optimizing patient care and limited health-care resourcesmanagement. We aim to assess
the clinical outcomes of severe COVID-19 patients admitted to an IMCU.
Methods: Observational, retrospective study including patients admitted to the IMCU
due to COVID-19 pneumonia during the months of March and April 2020. Patients were
stratified based on their requirement of transfer to the intensive care unit (ICU) and on
survival status at the end of follow-up. A multivariable Cox proportional hazards method
was used to assess risk factors associated with mortality.
Results: A total of 253 patients were included. Of them, 68% were male and median
age was 65 years (IQR 18 years). Ninety-two patients (36.4%) required ICU transfer.
Patients transferred to the ICU had a higher mortality rate (44.6 vs. 24.2%; p < 0.001).
Multivariable proportional hazards model showed that age ≥65 years (HR 4.14; 95%CI
2.31–7.42; p < 0.001); chronic respiratory conditions (HR 2.34; 95%CI 1.38–3.99; p
= 0.002) and chronic kidney disease (HR 2.96; 95%CI 1.61–5.43; p < 0.001) were
independently associated with mortality. High-dose systemic corticosteroids followed by
progressive dose tapering showed a lower risk of death (HR 0.15; 95%CI 0.06–0.40;
p < 0.001).
Conclusions: IMCU may be a useful tool for the multidisciplinary management of
severe COVID-19 patients requiring respiratory support and non-invasive monitoring,
therefore reducing ICU burden. Older age and chronic respiratory or renal conditions are
associated with worse clinical outcomes, while treatment with systemic corticosteroids
may have a protective effect on mortality.
Keywords: COVID-19, pneumonia, mortality, IMCU, ICU, non-invasive ventilation, high-flow nasal cannula,
intermediate care unit
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INTRODUCTION
Coronavirus disease 2019 (COVID-19) is a respiratory condition
caused by severe acute respiratory syndrome-coronavirus-2
(SARS-CoV-2) (1). Patients with COVID-19 may become
severely ill and require hospital admission, with estimated
hospitalization rates of 1 to 18%, increasing with older age
(2). Current recommendations state that patients with COVID-
19 related acute respiratory failure should be monitored, and
support with high-flow nasal cannula (HFNC) oxygen therapy
or non-invasive ventilation (NIV) should be considered when
conventional oxygen therapy fails (3). In this regard, during the
months of March and April of 2020, the COVID-19 pandemic
conditioned a significant increase in healthcare burden across
Europe, as 17 to 32% of admitted patients required critical
care management (4–7). The intensive care unit (ICU) beds
and invasive mechanical ventilators achieved their limits of
occupation, hence non-invasive supportive care was a valuable
option for maintaining respiratory conditions. Therefore, a
proper healthcare resource management was necessary to
warrant an adequate patient care.
Intermediate respiratory care units (IMCU) are a useful
resource for the management of complex patients that do not
require admission to the ICU, invasive mechanical ventilation
or invasive monitoring (8). IMCU can function as a space for
management escalation and de-escalation between the general
ward and the ICU, especially when patient monitoring is needed
and/or when respiratory support with HFNC or NIV is required
(8–10). Benefits of IMCU include reducing ICU admission time
and increasing ICU bed capacity, as well as lowering mortality
and health care costs (8, 10, 11). Although the role of the ICU is
well-known, there is scarce data regarding the outcomes of severe
COVID-19 patients managed in an IMCU during the pandemic.
To this date, there have been more than 158 million
reported cases worldwide, with over 3 million deaths (12).
Mortality is variable among hospitalized patients with COVID-
19 pneumonia. Studies from Chinese cohorts estimate a hospital
mortality of 4 to 28% (4, 5, 13). Furthermore, a recent study
from the United Kingdom showed an overall mortality of 26% in
admitted patients (7). Most of these deaths were related to sepsis,
respiratory failure, acute respiratory distress syndrome (ARDS)
and heart failure (4). Moreover, mortality rates of patients in
critical care are higher, ranging from 26 to 32% (7, 14), including
ICU and IMCU. Nevertheless, the specific mortality of COVID-
19 patients admitted to an IMCU has not been widely studied.
We aim to evaluate the outcomes of severely ill COVID-19
patients requiring monitoring and/or non-invasive respiratory
support admitted to an IMCU, and to identify clinical factors that
may have led to these results.
METHODS
Study Design
An observational and retrospective study was performed on
consecutive patients admitted to the IMCU of a tertiary
care hospital in Barcelona (Spain) throughout the months of
March and April 2020. The final date of follow-up was June
28, 2020. Study protocol was approved by the local ethics
committee (No. PR260/20). Inclusion criterion was admission
to IMCU due to respiratory failure related to COVID-19
pneumonia requiring non-invasive monitoring and/or non-
invasive respiratory support. Patients were diagnosed with
a positive polymerase chain reaction for SARS-CoV2 from
nasopharyngeal swab and the presence of pulmonary opacities
on chest X-ray. According to local protocol, IMCU admission
was limited to subjects with an oxygen saturation (SpO2) to
inspired oxygen fraction (FiO2) ratio lower than 200 but not
expected to require immediate support with invasive mechanical
ventilation. Subjects were admitted directly from the emergency
department or transferred from a regional hospital or general
wards due to clinical impairment. Exclusion criteria were: recent
admission to the ICU, as these patients had already shown
clinical improvement, subjects with COVID-19 pneumonia not
requiring oxygen support throughHFNC or NIV, and respiratory
failure due to any etiology other than COVID-19. Figure 1
shows the algorithm of multidisciplinary patient management
including specialists in respiratory medicine, critical care and
internal medicine.
Data Collection and Analysis
Demographic, clinical, radiological and laboratory data were
collected from electronic medical records for all patients at the
time of IMCU admission. All participants were treated according
to hospital protocols. Systemic corticosteroid therapy was divided
into four categories depending on dose and administration route,
as patients were treated before preliminary results from the
RECOVERY trial (15): (a) no corticosteroid treatment, (b) and
(c) intravenous (IV) bolus of 1–2mg/Kg/daymethylprednisolone
or its equivalent dexamethasone dose for 3 days, followed or not
by oral prednisone starting from 0.5 mg/Kg/day, tapering the
dose over 7 to 10 days; and (d) only oral prednisolone in doses
lower than 0.5 mg/Kg/day for 7 to 10 days. Treatment schemes
were chosen depending on clinical and radiological severity,
where more severe individuals received longer treatments and
higher doses. Patients were categorized depending on survival
status and ICU transfer requirement during hospitalization. ICU
admission criteria included cardiopulmonary arrest, sudden fall
in level of consciousness, invasive ventilation requirement and
shock requiring support with vasoactive drugs. The decision of
whether or not to transfer a patient to the ICU was always
made by a multidisciplinary team including pulmonologists and
intensive care physicians. For the survival analysis, clinical and
laboratory features were studied using criteria for ARDS (16)
and cut-off values identified in severe cases from previous studies
(4, 5, 17–19).
Statistical Analysis
Frequency and percentages were used to present categorical data,
and chi-squared test or Fisher’s exact test were used to evaluate
their differences. Continuous variables are expressed as mean
and standard deviation (SD) for normally distributed variables
or median and interquartile range (IQR) otherwise. ANOVA
and Student’s t test or their corresponding non-parametrical
tests (Kruskal–Wallis and Mann–Whitney U tests, respectively)
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FIGURE 1 | Algorithm of multidisciplinary patient management. Clinical worsening is defined as SpO2/FiO2 <100 and/or tachypnea >30 breaths per minute. Clinical
improvement is defined as SpO2/FiO2 >200 and respiratory rate <30 breaths per minute. *Daily multidisciplinary team assessment; +Transfer to ICU if IMV and/or
vasoactive drugs are required. COVID-19, coronavirus disease-2019; SpO2/FiO2, oxygen saturation to fraction of inspired oxygen ratio; IMCU, intermediate
respiratory care unit; ICU, intensive care unit; NIV, non-invasive ventilation; HFNC, high-flow nasal cannula; IMV, invasive mechanical ventilation.
were used to evaluate their differences, when required. Kaplan–
Meier curves were used for the survival analysis. In order
to identify factors associated with mortality, a multivariable
Cox proportional hazards analysis was performed including
significant variables from univariate analysis. A p-value < 0.05
was considered statistically significant. Data were analyzed using
R (software version 3.6.2).
RESULTS
Patient Description
A total of 291 patients were admitted to the IMCU during
the months of March and April of 2020 due to COVID-19
pneumonia. After excluding 38 patients that were previously
treated in the ICU, 253 patients were finally included. Of
them, 68% were male and median age was 65 years (IQR
18 years). The most frequent comorbidities were hypertension
(50.2%), dyslipidemia (47.8%) and diabetes mellitus (29.6%).
Demographic and clinical characteristics of included patients at
admission to IMCU are described in Table 1.
Clinical Outcomes
Ninety-two patients (36.4%) required transfer to the ICU. There
were no significant differences in age, gender or comorbidities
between ICU and non-ICU groups. However, patients requiring
ICU management had higher systemic inflammatory markers
and a significant lower SpO2/FiO2 ratio on admission. A
comparison of patient characteristics between those that were
admitted to the ICU and those who did not, is shown in Table 1.
A higher proportion of patients received home discharge
in the IMCU group compared to those that required transfer
to ICU (50.3 vs. 22.8%, respectively; p < 0.001). However, a
similar proportion of subjects needed admission to socio-health
centers or transfer to their regional hospital for convalescence.
Six patients of the ICU group were still hospitalized, while none
of the IMCU subjects were in the hospital at the end of follow-up.
A comparison of clinical outcomes between groups is presented
in Table 2.
Mortality
Eighty patients (31.6%) died during hospitalization. Main causes
of death were ARDS and septic shock. Patients requiring transfer
to the ICU had a higher mortality rate (44.6 vs. 24.2%; p< 0.001).
When comparing survivors and non-survivors, a significant
difference was observed regarding age (median 61 years, IQR
17 vs. median 72 years, IQR 10.3, respectively; p < 0.001).
Non-survivors had a higher proportion of comorbidities such
as dyslipidemia, chronic respiratory diseases and chronic kidney
disease. Furthermore, these patients had higher blood leukocyte
counts, serum lactate dehydrogenase (LDH), C-reactive protein
and D-dimer, and lower blood lymphocyte counts on admission
to the IMCU (Table 3).
We compared groups of deceased patients. Subjects who died
at the IMCU were significantly older (median 76 years, IQR 4.5
vs. median 66 years, IQR 12; p < 0.001). Nevertheless, similar
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Male, n (%) 172 (67.9%) 104 (64.6%) 68 (73.9%) 0.165
Age in years, median (IQR) 65 (18) 66 (19) 63 (15.3) 0.072
Comorbidities
Hypertension, n (%) 127 (50.2%) 85 (52.8%) 42 (45.7%) 0.336
Diabetes, n (%) 75 (29.6%) 44 (27.3%) 31 (33.7%) 0.356
Dyslipidemia, n (%) 121 (47.8%) 75 (46.6%) 46 (50%) 0.695
Obesity, n (%) 63 (24.9%) 40 (24.9%) 23 (25%) >0.999
Cardiovascular disease, n (%) 27 (10.7%) 19 (11.8%) 8 (8.7%) 0.577
Chronic respiratory disease, n (%)
Asthma 14 (5.5%) 8 (4.9%) 6 (6.5%) 0.789
COPD 17 (6.7%) 13 (8.1%) 4 (4.3%)
Interstitial lung disease 6 (2.4%) 3 (1.9%) 3 (3.3%)
Bronchiectasis 1 (0.4%) 1 (0.6%) 0
OSAS 15 (5.9%) 9 (5.6%) 6 (6.5%)
History of malignancy, n (%) 37 (14.6%) 24 (14.9%) 13 (14.1%) >0.999
Chronic liver disease, n (%) 22 (8.7%) 18 (11.2%) 4 (4.4%) 0.105
Chronic kidney disease, n (%) 27 (10.7%) 19 (11.8%) 8 (8.7%) 0.577
Immunosuppression, n (%) 13 (5.1%) 10 (6.2%) 3 (3.3%) 0.386
Symptoms
Dyspnea, n (%) 149 (58.9%) 86 (53.4%) 63 (68.5%) 0.027*
Cough, n (%) 189 (74.7%) 117 (72.7%) 72 (78.3%) 0.405
Fever, n (%) 211 (83.4%) 131 (81.4%) 80 (86.9%) 0.330
Myalgias, n (%) 71 (28.1%) 49 (30.4%) 22 (23.9%) 0.334
Diarrhea, n (%) 64 (25.3%) 38 (23.6%) 26 (28.3%) 0.503
Nausea, n (%) 22 (8.7%) 12 (7.5%) 10 (10.9%) 0.487
Days from symptom onset to hospital admission), median (IQR) 8 (5) 8 (5) 8 (5) 0.821
Days from symptom onset to IMCU admission), median (IQR) 10 (7) 10 (7) 9 (7.3) 0.176
Chest X-ray on admission
Bilateral opacities, n (%) 149 (58.9%) 143 (90.5%) 89 (96.7%) 0.113
Peripheral distribution of opacities, n (%) 189 (74.7%) 96 (60.8%) 48 (52.2%) 0.233
Laboratory blood tests
Leukocyte count (×109/L), median (IQR) 8.60 (5.6) 7.80 (4.8) 10.15 (6.5) <0.001*
Lymphocyte count (×109/L), median (IQR) 0.68 (0.6) 0.73 (0.6) 0.64 (0.6) 0.039*
Lactate dehydrogenase (U/L), median (IQR) 418 (221) 398 (220.5) 446 (237) 0.005*
C-Reactive protein (mg/L), median (IQR) 137 (177) 108 (148) 179.50 (188) <0.001*
Ferritin (µg/L), median (IQR) 1,443 (1,337) 1,479 (1,426) 1,410 (1,242.8) 0.829
D-dimer (µg/L), median (IQR) 531 (814.3) 506.50 (821.3) 599.50 (757.5) 0.446
Treatment
Lopinavir/Ritonavir, n (%) 202 (79.8%) 126 (78.3%) 76 (82.6%) 0.505
Remdesivir, n (%) 11 (4.4%) 2 (1.2%) 9 (9.8%) 0.004*
Hydroxychloroquine, n (%) 243 (96.1%) 151 (93.8%) 92 (100%) 0.035*
Tocilizumab, n (%) 124 (49%) 73 (45.3%) 51 (55.4%) 0.157
Systemic corticosteroids, n (%)
Intravenous bolus 114 (45.1%) 67 (41.6%) 47 (51.1%) 0.022*
Intravenous bolus + oral tapering regimen 52 (20.6%) 28 (17.4%) 24 (26.1%)
Oral tapering regimen 4 (1.6%) 3 (1.9%) 1 (1.1%)
SpO2/FiO2 ratio, median (IQR) 132.90 (52.5) 137.10 (74.3) 118.80 (37.1) <0.001*
Respiratory support
High-flow oxygen, n (%) 165 (65.2%) 88 (54.7%) 77 (83.7%) <0.001*
Non-invasive ventilation, n (%) 133 (52.6%) 58 (36%) 75 (81.5%) <0.001*
Invasive mechanical ventilation, n (%) 82 (32.4%) 0 82 (89.1%) <0.001*
ICU, intensive care unit; IQR, interquartile range; COPD, chronic obstructive pulmonary disease; OSAS, obstructive sleep apnea syndrome; SpO2, oxygen saturation; FiO2, fraction of
inspired oxygen; IMCU, Intermediate care unit.
*Indicates significant p-value < 0.05.
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Home discharge, n (%) 103 (40.7%) 81 (50.3%) 22 (23.9%) <0.001*
Socio-health center transfer, n (%) 70 (27.7%) 41 (25.5%) 29 (31.5%) >0.999
Deaths during admission, n (%) 80 (31.6%) 39 (24.2%) 41 (44.6%) 0.001*
Length of IMCU stay in days, median (IQR) 6 (7) 7 (6.3) 4 (5.3) <0.001*
Length of hospital stay in days, median (IQR) 16 (19) 13 (10.3) 31 (31) <0.001*
IQR, interquartile range; ICU, intensive care unit; IMCU, intermediate care unit.
*Indicates significant p-value < 0.05.
proportions of gender, comorbidities and laboratory findings on
admission were observed between groups.
Survival Analysis
Kaplan-Meier survival analysis identified a significant higher
mortality in patients of 65 years of age or older (Figure 2). Also,
significant differences in survival time were observed regarding
chronic respiratory and renal conditions and corticosteroid
treatment during hospitalization (Figure 3).
Variables that independently increased risk of death in
the multivariable Cox proportional hazards analysis included:
age equal or older than 65 years [hazard ratio (HR) 4.14;
95% confidence interval (CI) 2.31–7.42; p < 0.001]; chronic
respiratory conditions (HR 2.34; 95% CI 1.38–3.99; p = 0.002)
and chronic kidney disease (HR 2.96; 95% CI 1.61–5.43;
p < 0.001). Patients receiving high dose systemic corticosteroids
followed by or progressive dose tapering showed a significant
lower risk of death (HR 0.15; 95% CI 0.06–0.40; p < 0.001).
Regarding laboratory findings on admission, blood leukocyte
counts higher than 10× 109/L and lymphocyte counts lower than
0.4 × 109/L were associated with higher risk of death (HR 2.19;
95% CI 1.30–3.71; p= 0.003 and HR 2.05; 95% CI 1.19–3.53; p=
0.010). Furthermore, serum LDH higher than 445 U/L was also
independently associated with mortality (HR 1.83; 95% CI 1.04–
3.21; p = 0.035). Figure 4 shows the results for the multivariable
Cox proportional hazards model.
DISCUSSION
This is one of the first and largest studies to assess the
clinical outcomes of severe COVID-19 patients admitted to
an IMCU during the first wave of the pandemic. The
IMCU allows a secure environment for providing non-
invasive respiratory support and patient monitoring, potentially
improving healthcare resource management. Our patient model
management, including continuous assessment by specialists of
respiratory medicine, critical care and internal medicine showed
relatively low mortality rates and positive clinical outcomes
compared to results from other critical care cohorts. Factors
associated with higher mortality in these patients were older
age, chronic pulmonary or kidney diseases, while treatment with
systemic corticosteroid treatment was protective.
Patient characteristics and clinical presentation of the disease
were similar to what has been described in previous studies
(7, 18–20). Our cohort includes a large number of patients with
severe respiratory failure, determined by a median SpO2/FiO2
ratio of 132.90. These patients may have required admission to
ICU in hospitals without IMCU, possibly leading to further ICU
collapse. To this date, there is limited data addressing the specific
role of IMCU as a way of reducing the ICU transfer rate of
severe COVID-19 patients. A study by Lagi et al. showed that
improving nurse/patient ratio to 1:6 and using HFNC on regular
wards resulted in a 12% reduction of ICU transfer (21). In this
regard, our hospital rapidly increased the number of IMCU beds
due to the pandemic situation, maintaining a nurse/patient ratio
of 1:4 and non-invasive monitoring. In our cohort, only 36% of
patients admitted to an IMCU required upscalingmanagement to
the ICU. This resulted in a reduction of ICU burden and allowed
for more response time to face the rapid increase of severe cases.
A previous study by Heili-Frades et al. showed that IMCU may
avoid∼500.000 euros per year of hospital costs, especially in high
complexity patients requiring HFNC oxygen therapy or NIV (8).
Although the specific admission costs of COVID-19 patients have
not been estimated, the IMCU not only could help to improve
ICU bed availability, but also to lower overall healthcare costs.
All-cause mortality in our cohort was 31.6%, similar to what
has been observed in other cohorts. A recent study by Li et
al. showed that mortality in severe cases was 32.5% during
the 32 days follow-up period, regardless of respiratory support
requirement (18). Also, two cohorts of patients admitted to
critical care (ICU or IMCU), one from UK and the other
from Italy, reported a similar mortality rate (14). A multicenter
European cohort study demonstrated that the availability of
IMCU significantly reduced adjusted hospital mortality for adults
admitted to the ICU (11). However, data is scarce regarding the
mortality of severe COVID-19 patients specifically in an IMCU.
In this regard, Franco et al. observed that the implementation of
non-invasive respiratory support outside the ICU had favorable
results, with an overall mortality rate of 26.9% (22). Similarly, we
observed that mortality in IMCU patients who did not require
ICU admission was 24.2%, significantly lower than in the ICU
group. This may be expected, as most of the patients in the ICU
group were more severely ill and required invasive mechanical
ventilation. A large proportion of deceased patients received
respiratory support with NIV, as this was the escalation support
for those patients that continued to show clinical worsening
with HFNC, unless otherwise decided by the patient and/or the
multidisciplinary medical team. Although we cannot rule out the
Frontiers in Medicine | www.frontiersin.org 5 July 2021 | Volume 8 | Article 711027
Suarez-Cuartin et al. Outcomes of COVID-19 Management in an IMCU






Male, n (%) 121 (69.9%) 51 (63.8%) 0.403
Age, median (IQR) 61 (17) 72 (10.3) <0.001*
Comorbidities
Hypertension, n (%) 83 (47.9%) 44 (55%) 0.366
Diabetes, n (%) 49 (28.3%) 26 (32.5%) 0.597
Dyslipidemia, n (%) 73 (42.2%) 48 (60%) 0.012*
Obesity, n (%) 46 (26.6%) 17 (21.3%) 0.449
Cardiovascular disease, n (%) 16 (9.3%) 11 (13.8%) 0.390
Chronic respiratory disease, n (%)
Asthma 8 (4.6%) 6 (7.5%) 0.008*
COPD 8 (4.6%) 9 (11.3%)
Interstitial lung disease 1 (0.6%) 5 (6.3%)
Bronchiectasis 1 (0.6%) 0
OSAS 9 (5.2%) 6 (7.5%)
History of malignancy, n (%) 20 (11.6%) 17 (21.3%) 0.066
Hepatopathy, n (%) 19 (10.9%) 3 (3.8%) 0.097
Chronic kidney disease, n (%) 11 (6.4%) 16 (20%) 0.002*
Immunosuppression, n (%) 6 (3.5%) 7 (8.8%) 0.121
Symptoms
Dyspnea, n (%) 103 (59.5%) 46 (57.5%) 0.866
Cough, n (%) 134 (77.5%) 55 (68.8%) 0.185
Fever, n (%) 149 (86.1%) 62 (77.5%) 0.125
Myalgias, n (%) 53 (30.6%) 18 (22.5%) 0.235
Diarrhea, n (%) 45 (26%) 19 (23.8%) 0.819
Nausea, n (%) 14 (8.1%) 8 (10%) 0.794
Days from symptom onset to hospital admission), median (IQR) 8 (5) 8 (4.8) 0.457
Days from symptom onset to IMCU admission), median (IQR) 10 (7) 10 (7) 0.745
Chest X-ray on admission
Bilateral opacities, n (%) 158 (92.9%) 74 (92.5%) >0.999
Peripheral distribution, n (%) 105 (61.8%) 39 (48.8%) 0.071
Laboratory blood tests
Leukocyte count (×109/L), median (IQR) 8.20 (5.2) 10.20 (5.7) <0.001*
Lymphocyte count (×109/L), median (IQR) 0.75 (0.6) 0.52 (0.5) <0.001*
Lactate dehydrogenase (U/L), median (IQR) 395 (184.3) 476 (251) <0.001*
C-Reactive protein (mg/L), median (IQR) 108 (167) 169 (196.5) <0.001*
Ferritin (µg/L), median (IQR) 1,369 (1,213.5) 1,792 (1,444) 0.128
D-dimer (µg/L), median (IQR) 432 (784) 701 (1,756) <0.001*
Treatment
Lopinavir/Ritonavir, n (%) 134 (77.5%) 68 (85%) 0.222
Remdesivir, n (%) 9 (5.2%) 2 (2.5%) 0.510
Hydroxychloroquine, n (%) 164 (94.8%) 79 (98.8%) 0.177
Tocilizumab, n (%) 83 (47.9%) 41 (51.3%) 0.727
Systemic corticosteroids, n (%)
Intravenous bolus 70 (40.5%) 44 (55%) 0.002*
Intravenous bolus + oral tapering regimen 46 (26.6%) 6 (7.5%)
Oral tapering regimen 3 (1.7%) 1 (1.3%)
SpO2/FiO2 ratio, median (IQR) 137.10 (82.2) 123.39 (37.4) <0.001*
Respiratory support
High-flow oxygen, n (%) 110 (63.6%) 55 (68.8%) 0.509
Non-invasive ventilation, n (%) 64 (36.9%) 69 (86.3%) <0.001*
Invasive mechanical ventilation, n (%) 42 (24.3%) 40 (50%) <0.001*
Tracheostomy, n (%) 18 (10.4%) 11 (13.8%) 0.572
Transfer to ICU, n (%) 51 (29.5%) 41 (51.3%) 0.001*
Length of IMCU stay in days, median (IQR) 6 (8) 4 (5) <0.001*
Length of hospital stay in days, median (IQR) 18 (22) 12 (15) <0.001*
IQR, interquartile range; COPD, chronic obstructive pulmonary disease; OSAS, obstructive sleep apnea syndrome; SpO2, oxygen saturation; FiO2, fraction of inspired oxygen; IMCU,
intermediate care unit; ICU, intensive care unit.
*Indicates significant p-value < 0.05.
Frontiers in Medicine | www.frontiersin.org 6 July 2021 | Volume 8 | Article 711027
Suarez-Cuartin et al. Outcomes of COVID-19 Management in an IMCU
FIGURE 2 | Kaplan–Meier survival analysis by age and previous chronic respiratory conditions.
FIGURE 3 | Kaplan–Meier survival analysis by previous chronic renal disease and systemic corticosteroid treatment.
possible effect of delayed intubation on these results, all patients
with NIV were assessed continuously by pulmonologists and
intensive care physicians to determine whether intubation and
IMV were required or not.
Survival analysis showed significant differences between
patients of 65 years of age or older, and in those with chronic
renal and respiratory diseases. These conditions were identified
as independent risk factors for in-hospital mortality. Older age
has been associated with an increase in the risk of death in several
previous studies (18–20, 23). However, few of the published
multivariable models for mortality risk in COVID-19 patients
include chronic respiratory and renal diseases. Our results are in
agreement with recent observations showing that patients with
chronic obstructive pulmonary disease, interstitial lung diseases
or chronic kidney disease that require hospitalization because
of COVID-19 have higher risk of death (7, 20, 24). While the
overall in-hospital mortality rate of interstitial lung disease (ILD)
patients was 49% in the ISARIC4C study (24), the mortality
rate of those ILD patients in our IMCU cohort was 83.3%,
which suggests that the requirement of high-flux or non-invasive
mechanical ventilation in ILD patients with severe COVID-19
associates a poor prognosis. Regarding laboratory findings, our
model results show similarities with observations from prior
cohorts, where patients with leukocytosis, lymphopenia and
elevated serum LDH on admission have a higher mortality risk
(4, 18, 19, 23).
Concerning patient treatment, only systemic corticosteroids
were independently associated with a reduction of mortality
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FIGURE 4 | Multivariable Cox proportional hazards model for the assessment of in-hospital death risk.
in our cohort. Subjects receiving 3 days of high-dose
methylprednisolone or dexamethasone followed by 7 days
of oral dose tapering had a lower risk of death than those
who received shorter treatments or were not treated. The
positive effect of systemic corticosteroids has been described in
recent studies. In a cohort from Wuhan, patients treated with
methylprednisolone had a lower mortality rate (23). Also, a
preliminary report of the RECOVERY trial showed that patients
receiving dexamethasone for up to 10 days resulted in lower
all-cause mortality (15). Furthermore, a recent meta-analysis by
the World Health Organization Rapid Evidence Appraisal for
COVID-19 Therapies (REACT) Working Group concluded that
the administration of systemic corticosteroids in critically-ill
COVID-19 patients was associated with a lower 28-daymortality,
compared to usual care or placebo (25). Nevertheless, though
the beneficial effect is clear in severe cases, the optimal dose and
dose-reduction should be better evaluated for avoiding adverse
events at the same time than achieving a proper lung recovery.
This study has several limitations, mainly related to the
retrospective design of the analysis including a single center.
The lack of a control group (non-IMCU hospital) does not
allow to directly quantify the impact of IMCU in COVID-19
mortality or health-care burden. Also, our cohort included only
severe patients, as we focused on the role of IMCU in patient
management. This may limit the generalization of our results to
less severe cases. Furthermore, local treatment protocols changed
during the inclusion period due to the pandemic situation and the
scarce data on COVID-19, whichmay have influenced the clinical
outcomes of our study. However, the number of participants is
higher than most previous studies, and our results agree with
observations from different cohorts.
CONCLUSIONS
Our study shows that IMCU may be useful tools for the
multidisciplinary management of severe COVID-19 patients
requiring non-invasive respiratory support and monitoring,
therefore helping to reduce ICU burden. Older age and chronic
respiratory or renal conditions are associated with worse
clinical outcomes while treatment with systemic corticosteroids
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may have a protective effect on mortality. These results may
help to further validate the feasibility of IMCU during the
COVID-19 pandemic.
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